El Hassane Larhrib

Speaker for pharma conferences europe-El Hassane Larhrib

Title: Dry powder inhalers - Challenges and opportunities in delivering drugs to the lungs

El Hassane Larhrib

University of Huddersfield, UK


Dr Larhrib was educated at theUniversity of Sciences and Technology, Lille Iand the faculty of Pharmacy, Lille II, France where he obtained an MSc Biochem, DU Pharm, DESS Pharm. Tech. and a certificate in Pharm. Chemistry. He moved to the UK to do a PhD in Pharmaceutical technology at Liverpool John Moores University, using high speed compaction simulator to fundamentally study the mechanism of compaction of pharmaceutical powders under the supervision of Dr. James Wells and Prof. Mike Rubinstein (1994-1998). Following his PhD, Dr Larhrib worked for 4 years (1998-2002) as Senior Research Fellow in Pharmaceutics at the Department of Pharmacy, King’s College London.Heworked atLiverpool John Moores University as a Senior lecturer in Pharmaceutics for 6 years (2002-2007) before joining the industry; Solid Solution Limited, Liverpool (2007-2010).He was involved in cosmetic products development and manufacture. He moved to Medway school of Pharmacy before joining the University of Huddersfield as a Senior lecturer in Pharmaceutics in July 2011. Dr. Larhrib is a regular reviewer for many international Pharmaceutical journals and member of editorial board of journal of International Research in Medical and Pharmaceutical Sciences and British Journal of Pharmaceutical Research.


I will start my presentation by sharing with the audience the importance of particle engineering for different pharmaceutical applications such as oral and inhaled products. In the second part of mytalk, I will stress the importance of dry powder inhaler (DPI) devices use and their effect on treatment compliance and disease management in patients suffering from respiratory diseases (e. g. Asthma and Chronic Obstructive Pulmonary Disease [COPD]). Finally, I will be discussing the issues associated with: i) inhalation manoeuvre parameters and drug delivery by DPIs to the lungs; ii) pharmacopoeial methodologies for testing DPIs in-vitro